SOdium-glucose CO-transporter inhibition in patients with Type 2 Diabetes and Ischemic Heart Failure (SOCODIHF)

Next Previous
Trial Profile

SOdium-glucose CO-transporter inhibition in patients with Type 2 Diabetes and Ischemic Heart Failure (SOCODIHF)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Chronic heart failure; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SOCODIHF

    • Most Recent Events

    • 14 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top